Kevin Ali - Mar 31, 2025 Form 4 Insider Report for Organon & Co. (OGN)

Role
Chief Executive Officer, Director
Signature
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Kevin Ali
Stock symbol
OGN
Transactions as of
Mar 31, 2025
Transactions value $
-$876,288
Form type
4
Date filed
4/2/2025, 05:32 PM
Previous filing
Feb 24, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OGN Common Stock Options Exercise $0 +48.8K +24.39% $0.00 249K Mar 31, 2025 Direct
transaction OGN Common Stock Tax liability -$391K -27K -10.84% $14.51 222K Mar 31, 2025 Direct F1
transaction OGN Common Stock Options Exercise $0 +39K +17.58% $0.00 261K Mar 31, 2025 Direct
transaction OGN Common Stock Tax liability -$313K -21.6K -8.27% $14.51 239K Mar 31, 2025 Direct F1
transaction OGN Common Stock Options Exercise $0 +21.5K +8.98% $0.00 261K Mar 31, 2025 Direct
transaction OGN Common Stock Tax liability -$172K -11.9K -4.56% $14.51 249K Mar 31, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Stock Option (right to buy) Award $0 +1.07M $0.00 1.07M Mar 31, 2025 Common Stock 1.07M $14.89 Direct F2
transaction OGN Restricted Stock Units Award $0 +218K $0.00 218K Mar 31, 2025 Common Stock 218K Direct F3, F4
transaction OGN Restricted Stock Units Options Exercise $0 -48.8K -33.33% $0.00 97.5K Mar 31, 2025 Common Stock 48.8K Direct F3, F5
transaction OGN Restricted Stock Units Options Exercise $0 -39K -50% $0.00 39K Mar 31, 2025 Common Stock 39K Direct F3, F6
transaction OGN Restricted Stock Units Options Exercise $0 -21.5K -100% $0.00 0 Mar 31, 2025 Common Stock 21.5K Direct F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
F2 The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028.
F3 Each RSU converts into one share of Organon common stock.
F4 The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.
F5 On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.
F6 On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026.
F7 On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.